为了提高别嘌醇使用的安全性,我们建议痛风患者在服用别嘌醇前,进行HLA-B*5801等位基因检测,以提高用药的安全性。 参考文献 1. Richette P, et al. 2016 updated EULAR evidence-based recommendations for the management of gout[J].Ann Rheum Dis2017;76:29–42. 2. 中华医学会风湿病学分会. 2016中国痛风...
Therefore, in 2012, the American College of Rheumatology updated the gout management guidelines, which recommended that before using allopurinol, people at high risk of severe allergic reactions (Han Chinese, Korean, and Thai) should undergo HLA-B*5801 allele testing. Technical Data ...
HLA-B5801 genotyping of gout reduces costsNo Abstract available for this article.doi:10.1007/s40274-014-1424-8NoneSpringer International PublishingPharmacoeconomics & Outcomes News
HLA-B *58∶01等位基因与不同种族人群服用别嘌醇致SCAR相关性的研究结果显示,中国台湾、香港和大陆多个地区汉族人群以及泰国、韩国HLA-B*58∶01基因频率较高的种族人群服用别嘌醇后发生的SCAR与HLA-B *58∶01等位基因具有明显相关性,日本、欧洲等HLA-B *58∶01基因频率较低的种族人群服用别嘌醇后发生SCAR与...
目的分析慢性肾脏病合并高尿酸血症患者降尿酸药物应用和HLA-B*5801等位基因检测的合理性方法收集2015年7月至2017年6月在西安交通大学第一附属医院进行HLA-B*5801等位基因检测并应用苯溴马隆、别嘌醇或非布司他治疗的慢性肾脏病合并高尿酸血症患者的病历资料进行回顾性分析。根据有关指南、专家共识及药品说明书制订了...
Johnson syndrome in response tocarbamazepine(a drug used to treat seizures). Another version, HLA-B*5801, is associated with an increased risk of severe skin reactions in people treated withallopurinol(a drug used to treat gout, which is a form of arthritis caused byuric acidin the joints)....
HLA-B*5801等位基因检测方法的合理应用率为50.2%(101/201),不合理应用的100例患者中34例不适于使用别嘌醇[eGFR&15 ml/(min·1.73 m2)且未行透析],66例为适于使用别嘌醇、HLA-B*5801等位基因阴性但未使用别嘌醇。结论 我院慢性肾脏病合并高尿酸血症患者降尿酸药物应用和HLA-B*5801等位基因检测均存在不...
【专利摘要】本发明属药物基因组学和基因诊断领域,涉及检测HLA-B*5801等位基因的方法,包括:取待测样本DNA,用三对特异性引物和一对内参引物,用序列特异性引物法扩增DNA片段后用琼脂糖凝胶电泳分析扩增结果,或,抽提样本DNA后,用一对特异性引物、一对内参引物和3条荧光探针,用Taqman探针法在荧光定量PCR仪上扩增DNA片...
At the same time, genotyping tests for single loci of HLA-I class B locus such as B27 and B5801 also play an important role in personalized selection of drugs, such as auxiliary diagnosis of ankylosing spondylitis and gout medication guidance. HLA-B*1502 has also been confirmed to be highly...
5.4. Allopurinol and HLA-B*58:01 Allopurinol is a commonly used medication for treating hyperuricemia and gout. Studies have shown that HLA-B*58:01 carriers face a significantly increased risk of severe drug hypersensitivity reactions, such as SJS, TEN, and DRESS when treated with allopurinol (...